share_log

ANI Pharmaceuticals (NASDAQ:ANIP) Rallies 5.6% This Week, Taking Three-year Gains to 35%

ANI Pharmaceuticals (NASDAQ:ANIP) Rallies 5.6% This Week, Taking Three-year Gains to 35%

ani pharmaceuticals(纳斯达克:ANIP)本周上涨5.6%,为期三年的涨幅达35%
Simply Wall St ·  2024/11/09 09:08

By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. For example, the ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) share price is up 35% in the last three years, clearly besting the market return of around 16% (not including dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 18% in the last year.

通过购买指数基金,您可以轻松地与市场收益大致匹配。但如果您以有吸引力的价格购买优质业务,您的投资组合回报率可能会超过平均市场回报。例如,ANI Pharmaceuticals(纳斯达克:ANIP)股价在过去三年中上涨了35%,明显优于大约16%的市场回报率(不包括分红)。然而,最近的回报并不像那样令人印象深刻,该股票在过去一年仅上涨了18%。

Since it's been a strong week for ANI Pharmaceuticals shareholders, let's have a look at trend of the longer term fundamentals.

由于对ANI Pharmaceuticals股东来说,这是一个强劲的一周,让我们来看一下长期基本面的趋势。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

市场有时毫无疑问是有效的,但股票价格并不总是反映基本业务表现。一种有缺陷但合理的方法是比较每股收益(EPS)和股票价格,以评估围绕公司的情绪如何变化。

ANI Pharmaceuticals became profitable within the last three years. That would generally be considered a positive, so we'd expect the share price to be up.

ANI Pharmaceuticals在过去三年内实现了盈利。这通常被认为是积极的,因此我们预期股价会上涨。

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

下图显示了EPS随时间的变化情况(如果您单击该图像,则可以查看更多详细信息)。

big
NasdaqGM:ANIP Earnings Per Share Growth November 9th 2024
纳斯达克GM:ANI Pharmaceuticals每股收益增长2024年11月9日

It is of course excellent to see how ANI Pharmaceuticals has grown profits over the years, but the future is more important for shareholders. If you are thinking of buying or selling ANI Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

看到ANI Pharmaceuticals多年来利润增长当然是卓越的,但未来对股东来说更为重要。如果您正在考虑买入或卖出ANI Pharmaceuticals股票,您应该查看这份免费的详细报告以了解其资产负债表。

A Different Perspective

另一种看法

ANI Pharmaceuticals shareholders gained a total return of 18% during the year. But that was short of the market average. The silver lining is that the gain was actually better than the average annual return of 2% per year over five year. It is possible that returns will improve along with the business fundamentals. It's always interesting to track share price performance over the longer term. But to understand ANI Pharmaceuticals better, we need to consider many other factors. For instance, we've identified 2 warning signs for ANI Pharmaceuticals that you should be aware of.

ANI Pharmaceuticals股东在这一年总回报率为18%。但这低于市场平均水平。好消息是收益实际上优于过去五年平均每年2%的年度回报率。随着业务基本面的改善,回报可能会提高。长线追踪股价表现总是很有趣。但要更好地了解ANI Pharmaceuticals,我们需要考虑许多其他因素。例如,我们已经发现了ANI Pharmaceuticals的2个警告信号,您应该注意。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

当然,您可能通过在其他地方寻找会找到一笔极好的投资。因此,请查看我们预计会增长收入的公司免费名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发